Items Tagged ‘Alk 1’

March 7, 2017

Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC


The US Food and Drug Administration (FDA) granted Priority Review for the expanded use of Zykadia® (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The FDA also granted Breakthrough Therapy designation to Zykadia for the first-line […]

View full entry

Tags: Alk 1, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, Zykadia® ceritinib